Pediatric clinical trials market

Pediatric Clinical Trials Market, by Clinical Trial Phase (Pre-clinical, Phase I, Phase II, and Phase III), by Study Design (Treatment Studies and Observational Studies), by Medical Condition (Neuropsychiatric Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive Diseases and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Oct 2022
CMI397
313 Pages
Excel & Pdf
Pharmaceutical

Summary

Children are a special group of people with clear physiological and developmental distinctions from adults. To create age-specific, empirically-verified medicines and interventions and to ascertain and enhance the greatest medical care currently accessible, clinical studies in children are crucial. Children's clinical trials are crucial because they aid in the discovery of the most effective pediatric preventments. Children are not just miniature adults, they have quite diverse physiological processes going on as they transition from infancy through adolescence and maturity. Instead of just altering adult dosages and therapies for children because their bodies function differently, it is critical to develop pediatric-specific medications and preventments.

Global pediatric clinical trials market is estimated to be valued at US$ 14,869.5 million in 2022 and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030).

Figure 1. Global Pediatric Clinical Trials Market Share (%), by Clinical Trial Phase, 2022

Increasing demand for new vaccines and other biologic products to prevent various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis is expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC) factsheet in 2018, around 470,000 children had active epilepsy in the U.S., which was estimated to be around 0.6% of children aged 0-17 years.

Figure 2. Global Pediatric Clinical Trials Market Share (%), by Region, 2022

Increasing population of children is expected to drive market growth during the forecast period.

Increasing population of children is expected to drive market growth during the forecast period. For instance, according to Humanium, which is an international child sponsorship Non-Governmental Organisation (NGO) dedicated to stopping violations of children’s rights throughout the world, stated that the pediatric population in 2021 was about 2.2 billion globally.

Pediatric Clinical Trials Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 14,869.5 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	9.3%	2030 Value Projection:	US$ 30,311.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Clinical Trial Phase: Pre-clinical, Phase I, Phase II, Phase III By Study Design: Treatment Studies, Observational Studies By Medical Condition: Neuropsychiatric Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive, Others
Companies covered:	Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc
Growth Drivers:	Increasing demand for new vaccines and other biologic products to prevent various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis Increasing population of children
Restraints & Challenges:	High termination rate of pediatric clinical trials due to various reasons

Global Pediatric Clinical Trials Market– Impact of Coronavirus (COVID-19) Pandemic

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. Furthermore, according to the Centers for Disease Control and Prevention, as of April 2, 2020, around 2,572 (1.7%) cases of COVID-19 were registered in patients younger than 18 years in the U.S. Therefore, market players and research institutes are focusing on research and development activities by initiating clinical trials of drugs for the preventment of COVID-19 in children. Similarly, the University of Calgary, which is a public research university located in Alberta, Canada, initiated an observational study on March 18, 2020 to determine the clinical characteristics and outcomes of children potentially infected by COVID-19. Furthermore, research institutes are conducting observational studies to understand the impact of COVID-19 in various hospital departments. For instance, the South Egypt Cancer Institute, which provide medical education, training of researchers and physicians in the oncology field, initiated an observational study on May 15, 2020 to determine the effect of the COVID-19 pandemic on patients in the pediatric cancer care divisions in Egypt and the UAE.

Global Pediatric Clinical Trials Market: Key Developments

In June, 2020, Gilead Sciences initiated phase 2/3 clinical trials, to evaluate the safety, efficacy, tolerability, and pharmacokinetics of Remdesivir, an antiviral drug, in pediatric patients with coronavirus disease 2019 (COVID-19).

In November 2018, Synteract, which is a service clinical research organization (CRO) focused on the emerging biopharma segment, acquired KinderPharm, which is a clinical stage, specialty pharmaceutical company with expert resources focused exclusively on pediatric drug development. This acquisition will help Synteract, to strengthen its pediatric center of development.

Global Pediatric Clinical Trials Market: Restraint

The major factors that hinder growth of the global pediatric clinical trials market include high termination percentage of pediatric clinical trials due to several reasons. Pediatric trials have high percentage of failure due to reasons such as patient accrual. Other issues include behavioral problem and trial conduct issues such as inaccurate dosing, difficulty in formulation, and informative termination along with regulatory issues and drug toxicity during clinical trials.

Key Players

Major players operating in the global pediatric clinical trials market include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.

Table of Content

Table of Contents

*Browse 36 market data tables and 31 figures on “Global Pediatric Clinical Trials Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

Global Pediatric Clinical Trials Market, By Clinical Trial Phase :

Pre-clinical
Phase I
Phase II
Phase III

Global Pediatric Clinical Trials Market, By Study Design:

Treatment Studies
Observational Studies

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global pediatric clinical trials market during the forecast period (2022-2030)?

Global pediatric clinical trials market size is estimated to be valued at US$ 14,869.5 million in 2022 and is expected to exhibit a CAGR of 9.3% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing demand for new vaccines and other biologic products to prevent various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis and increasing population of children are expected to drive the market growth.

Which is the leading clinical trial phase segment in the market?

Phase 2 is the leading clinical trial phase segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include high termination rate of pediatric clinical trials due to various reasons.

Which are the major players operating in the market?

Major players operating in the market include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.